Soleno Therapeutics (SLNO) Sparks Confidence Amid Topline Outperformance

Core Viewpoint - Soleno Therapeutics (NASDAQ:SLNO) is identified as a promising biotechnology stock with significant upside potential, supported by positive analyst ratings and strong sales performance. Group 1: Analyst Ratings and Price Targets - Ram Selvaraju from H.C. Wainwright increased the price target for Soleno Therapeutics from $110 to $120, indicating an upside potential of nearly 211% and reaffirming a Buy rating [1] - Wells Fargo analyst Derek Archila maintained an Overweight rating and raised the price target from $106 to $114, suggesting a revised upside potential of 195% [3] Group 2: Financial Performance and Product Development - The fourth-quarter earnings for Vykat extended-release exceeded expectations, although new PSFs did not meet targets; management aims for approximately 250 new starts per quarter, excluding seasonal effects [4] - Soleno Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases, with its leading product being Diazoxide Choline Extended-Release tablets, VYKAT XR, which began commercialization in April 2025 following FDA approval [5]